Cellectricon Launches World’s First System for High Throughput RNAi

Gothenburg, Sweden, March 27, 2008: Cellectricon, a leading provider of

screening solutions for drug discovery, today announced the launch of the new Cellaxess(R)HT System. The world’s first fully automated high throughput transfection system enables reagent-free delivery of genetic material to a wide range of biologically relevant cell types. The system will be introduced at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6-10.

Cellectricon has developed Cellaxess(R)HT in close collaboration with

leading research groups to meet the increasing demand for a technology

capable of genome-wide RNAi screening.

“We are very pleased to meet the industry’s demand by bringing this

state-of-the-art system to the market.” says Dr. Mattias Karlsson, CEO of

Cellectricon. “Cellaxess(R)HT will revolutionize target discovery by opening

the door to using more biologically relevant cell types in genome-wide RNAi


About the Cellaxess(R)HT system

Cellaxess(R)HT addresses the critical need for high throughput delivery of

siRNA and cDNA to hard to transfect cells in several cell-based screening

assays. Cellaxess(R)HT is the only fully automated system on the market

allowing for high throughput transfection of cells in culture directly in

384-well microplates. The system enables reagent-free delivery to a wide

range of biologically relevant cell types with excellent efficiency and

viability at a throughput of 50 000 wells per day.

About Cellectricon

Cellectricon is a key innovator and solutions provider of advanced

cell-based screening products to accelerate biotechnology and drug discovery.

The company’s successfully launched products are aimed at critical

bottlenecks in the drug discovery process and have been adopted by

top-reference customers including the top ten pharmaceutical companies. To

date, the company has launched two products with exceptional market

acceptance targeting the ion channel screening and transfection markets. The company utilizes state-of-the-art interfaces to biological systems by

employing novel microfabrication technologies and smart engineering

solutions. This enables completely new types of assays and devices with

superior performance characteristics and robustness.

< | >